BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schreiber S, Yamamoto K, Muniz R, Iwura T. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. Pharmacol Res Perspect 2020;8:e00604. [PMID: 32500668 DOI: 10.1002/prp2.604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pedersen ME, Østergaard J, Jensen H. Quantification of Structural Integrity and Stability Using Nanograms of Protein by Flow-Induced Dispersion Analysis. Molecules 2022;27:2506. [DOI: 10.3390/molecules27082506] [Reference Citation Analysis]
2 Gangwar N, Priyanka P, Rathore AS. Achieving charge variant profile of innovator molecule during development of monoclonal antibody based biosimilars – use of media components. Biochemical Engineering Journal 2022. [DOI: 10.1016/j.bej.2022.108438] [Reference Citation Analysis]
3 Nupur N, Joshi S, Gulliarme D, Rathore AS. Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms. Front Bioeng Biotechnol 2022;10:832059. [DOI: 10.3389/fbioe.2022.832059] [Reference Citation Analysis]
4 Yonemura T, Yazawa R, Haranaka M, Kawakami K, Takanuma M, Kanzo T, Stefanidis D, Arai Y. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. BMC Pharmacol Toxicol 2022;23:6. [PMID: 34998419 DOI: 10.1186/s40360-021-00545-3] [Reference Citation Analysis]
5 Rathore A, Malani H. Need for a risk-based control strategy for managing glycosylation profile for biosimilar products. Expert Opin Biol Ther 2021;:1-9. [PMID: 34431439 DOI: 10.1080/14712598.2021.1973425] [Reference Citation Analysis]
6 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel) 2021;14:189. [PMID: 33669108 DOI: 10.3390/ph14030189] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Alsamil AM, Giezen TJ, Egberts TC, Leufkens HG, Gardarsdottir H. Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals 2021;69:30-7. [PMID: 33454195 DOI: 10.1016/j.biologicals.2020.12.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]